Haleon (NYSE:HLN) Earns Buy Rating from Analysts at HSBC

HSBC began coverage on shares of Haleon (NYSE:HLN) in a research report released on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating on the stock.

Separately, Argus reaffirmed a buy rating on shares of Haleon in a report on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy.

Haleon Stock Performance

Shares of HLN opened at $8.11 on Wednesday. The stock has a 50 day moving average price of $8.30 and a 200 day moving average price of $8.29. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $37.03 billion, a price-to-earnings ratio of 28.96, a price-to-earnings-growth ratio of 2.12 and a beta of 0.29. Haleon has a 52-week low of $7.70 and a 52-week high of $9.05.

Haleon Announces Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Thursday, May 16th. Stockholders of record on Friday, March 15th will be issued a $0.1064 dividend. This represents a dividend yield of 1.8%. The ex-dividend date of this dividend is Thursday, March 14th. Haleon’s payout ratio is currently 75.00%.

Institutional Investors Weigh In On Haleon

Several large investors have recently modified their holdings of HLN. Ironwood Wealth Management LLC. acquired a new stake in shares of Haleon in the third quarter valued at approximately $70,000. Tower Research Capital LLC TRC purchased a new stake in shares of Haleon during the third quarter worth approximately $115,000. Credit Suisse AG purchased a new stake in shares of Haleon during the third quarter worth approximately $76,000. Guggenheim Capital LLC purchased a new stake in shares of Haleon during the third quarter worth approximately $119,000. Finally, BlackRock Inc. purchased a new stake in shares of Haleon during the third quarter worth approximately $10,366,000. 6.67% of the stock is owned by institutional investors and hedge funds.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.